Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749401 | 1.00 | ERBB2 (0.62) | ERBB2 | |
| SCHEMBL3075346 | 0.84 | ERBB2 (0.67) | ERBB2 | |
| SCHEMBL3075344 | 0.84 | ERBB2 (0.67) | ERBB2 | |
| SCHEMBL5749650 | 0.82 | ERBB2 (0.61) | ERBB2 | |
| SCHEMBL5749646 | 0.82 | ERBB2 (0.61) | ERBB2 | |
| SCHEMBL4499820 | 0.81 | ERBB2 (0.65) | ERBB2 | |
| SCHEMBL4499821 | 0.81 | ERBB2 (0.65) | ERBB2 | |
| SCHEMBL6763688 | 0.81 | ERBB2 (0.55) | ERBB2 | |
| SCHEMBL6763690 | 0.81 | ERBB2 (0.55) | ERBB2 | |
| SCHEMBL5558914 | 0.80 | ERBB2 (0.53) | ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984653-B2 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-10 | — | — | US | disclosed |
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1439178-A1 | HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | ABL1, JAK1, BTK | ERBB2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.